Condensed Consolidated Statements Of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011		Dec. 31, 2010
Operating activities:
Net income	$ 9,620	$ 28,122		$ 21,081
Adjustments to reconcile net income to net cash provided by operating activities:
Non-cash expense related to stock-based compensation	3,897	3,108		2,224
Depreciation and amortization	3,449	2,942		556
Realized gain on investments				(226)
Other non-cash expense				249
Intangible asset impairment (Note 7)	42,728
Change in fair value of contingent consideration	(15,422)	(3,495)
Deferred taxes, net	(6,785)	(1,602)
Other long-term liabilities	(232)	(222)		11
Changes in operating assets and liabilities:
Accounts receivable, net	356	(2,730)	[1]	(9,277)
Inventories	801	(2,269)	[1]	3,115
Prepaid expenses and other assets	(156)	976		(674)
Accounts payable	2,195	945		1,543
Accrued and other current liabilities	3,070	3,680		2,199
Deferred revenue				(141)
Net cash provided by operating activities	43,521	29,455		20,660
Investing activities:
Acquisition of NovaMed, net of cash acquired		(21,256)
Purchases of available-for-sale investments	(75)	(1,580)		(10,266)
Proceeds from the sale or maturities of available-for-sale investments		4,682		7,283
Proceeds from the sale or maturity of trading security				1,800
Purchases of property and equipment	(1,128)	(686)		(133)
Net cash used in investing activities	(1,203)	(18,840)		(1,316)
Financing activities:
Repurchase of common stock	(24,836)	(3,495)
Repayment of line of credit	(2,500)
Proceeds from borrowing on short-term loan	1,445			2,500
Increase in restricted cash related to short-term loan	(2,300)
Proceeds from issuances of common stock	3,492	6,322		1,401
Net cash (used in) provided by financing activities	(24,699)	2,827		3,901
Effect of exchange rate changes on cash and cash equivalents	(45)	195		85
Net increase in cash and cash equivalents	17,574	13,637		23,330
Cash and cash equivalents, beginning of period	66,654	53,017		29,687
Cash and cash equivalents, end of period	84,228	66,654		53,017
Supplemental disclosure of cash flow information:
Income taxes paid related to foreign operations	1,893	1,102		829
Interest and unused line fees paid related to borrowings	$ 136	$ 169		$ 37

[1] Changes to net cash used in accounts receivable and inventory mainly related to the Company changing from the “sell-in” method to the “sell-through” method of revenue recognition for certain Pfizer products sold by the Company.